Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$41.41+1.0%$37.00$6.21▼$47.84$2.59B2.19671,726 shs512,890 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences0.00%-2.88%+21.47%-7.65%+500.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$41.41+1.0%$37.00$6.21▼$47.84$2.59B2.19671,726 shs512,890 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences0.00%-2.88%+21.47%-7.65%+500.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKODKodiak Sciences 2.63Moderate Buy$42.141.77% UpsideCurrent Analyst Ratings BreakdownLatest KAV, JLP, HE1, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2026KODKodiak Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)Latest KAV, JLP, HE1, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026KODKodiak Sciences-$0.97N/AN/AN/AN/AN/A5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKODKodiak SciencesN/A3.543.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipKODKodiak Sciences44.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKODKodiak Sciences9062.58 million34.79 millionOptionableCTL, KOD, AFRK, and 1SN HeadlinesRecent News About These CompaniesKodiak Sciences (NASDAQ:KOD) Trading 6.6% Higher - What's Next?July 17, 2026 | marketbeat.comY Intercept Hong Kong Ltd Sells 27,959 Shares of Kodiak Sciences Inc. $KODJuly 15, 2026 | marketbeat.comTraders Purchase Large Volume of Kodiak Sciences Call Options (NASDAQ:KOD)July 10, 2026 | marketbeat.comKodiak Sciences Inc.June 30, 2026 | barrons.com10 mid-cap US healthcare stocks with the strongest momentum gradesJune 24, 2026 | msn.comKodiak Sciences: Clinical Redemption Is Turning Into Platform LeverageJune 16, 2026 | seekingalpha.comKodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should KnowJune 9, 2026 | fool.comKodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing PlansJune 7, 2026 | finance.yahoo.comKodiak Sciences Inc. (KOD) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowJune 5, 2026 | seekingalpha.comKodiak Sciences Stockholders Back Directors and Governance ProposalsJune 4, 2026 | tipranks.comKodiak Stock Rises 35% in 3 Months: Here's What You Need to KnowJune 4, 2026 | zacks.comKodiak Sciences to Present at 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | prnewswire.comWhy One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping RallyMay 17, 2026 | fool.comKodiak Sciences (KOD) price target increased by 16.91% to 66.30May 14, 2026 | msn.comChardan Capital upgrades Kodiak Sciences (KOD)May 11, 2026 | msn.comA Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For ZenkudaMay 11, 2026 | finance.yahoo.comZenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)May 10, 2026 | finance.yahoo.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 8, 2026 | finanznachrichten.deKodiak's Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 8, 2026 | zacks.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesApril 30, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTL, KOD, AFRK, and 1SN Company DescriptionsKodiak Sciences NASDAQ:KOD$41.41 +0.39 (+0.95%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$41.08 -0.33 (-0.80%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
